[PRNewswire] Alamar Biosciences Announces Enhanced Features

NULISAseq CNS Disease Panel 120

-- Expanding NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays

-- First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research

FREMONT, Calif. May 16, 2025 /PRNewswire=YONHAP/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217, pTau181, pTau231, and total tau (tTau) protein measured directly from blood samples—delivering unprecedented sensitivity and specificity for the study of neurodegenerative diseases.

Phosphorylated tau has emerged as a critical biomarker for early detection and monitoring of Alzheimer's disease and other tauopathies. The new additions to the CNS Disease 120 Panel are specifically designed to detect brain-derived forms of pTau, overcoming the limitations of current assays that cannot distinguish between peripheral and central tau species. This allows for the simultaneous measurement of two suites of multiple pTaus and tTau species, one specific for brain-derived and one combining brain- and peripheral tissue-derived Tau species.

"Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology," said Dr. Yuling Luo, CEO, Founder and Chairman of Alamar Biosciences. "By integrating assays for pTau217, pTau181, pTau231, and total tau into our NULISAseq CNS Disease 120 Panel, we are enabling scientists to explore the full spectrum of tau pathology with exceptional sensitivity and throughput. This advancement is poised to accelerate biomarker-driven research and drug development in Alzheimer's Disease and related neurodegenerative disorders."

"The ability to detect brain-derived pTau species directly from blood represents a transformative step in the early detection and monitoring of Alzheimer's Disease (AD) and related disorders," said Nicholas Ashton, Ph.D., Director of Neurodegenerative Biomarker Research at Banner Health. "Until now, we've been unable to differentiate between brain-derived and peripheral pTaus in a multiplexed manner. Recent evidence has underlined the importance of being able to detect brain-derived pTau for greater specificity for AD. Alamar's new CNS panel offers an unprecedented opportunity to further improve the diagnostic accuracy and clinical utilities of these biomarkers, which will dramatically impact patient care and clinical research."

Alamar Biosciences remains committed to partnering with the neuroscience community to unlock biomarker insights that drive earlier diagnosis, patient stratification, and therapeutic monitoring.

For more information about the NULISAseq CNS Disease Panel 120 and Alamar Biosciences' portfolio of proteomic solutions, visit www.alamarbio.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

Source: Alamar Biosciences, Inc.

[※ Editor's note = This PRESS RELEASE was provided by the news provider, and Yonhap has not edited the content in any way, nor does it reflect the editorial direction of Yonhap.]

(END)